WASHINGTON (Reuters) – Merck, an international pharmaceutical company, has developed a capsule to protect against the corona virus and its contagious disease, Covid 19, which reduces hospital seizures and deaths. Can also dramatically reduce the rate of.
In the second phase of medical trials (Phase Two Clinical Trials), the capsule was successfully tested in 775 volunteers from the United States and other countries who were infected with the corona virus.
All volunteers were given this capsule twice a day, for five consecutive days. None of the volunteers who used it reached the hospital or died of the corona virus.
The capsule is also effective against a delta variant of the corona virus, which is currently the leading cause of the Covid 19 global epidemic, according to a Merck & Co. press release.
Merck has also requested the US Food and Drug Administration (FDA) to approve the capsule on an emergency basis.
On the other hand, a large number of different Asian countries have made advance bookings for this capsule so that they can control this epidemic at home as soon as possible.
Other coronavirus pills and capsules are being developed by various agencies, and it is hoped that by the end of this year we will not only have an abundance of vaccines to fight the Covid 19 epidemic, but also capsules and capsules to fight the disease. Tablets will also be available.